Dispensing Pharmacy Bankruptcy Trends (FY2025): “Monzen” Pharmacies Near Hospitals Face Hardship; Bankruptcies to Hit 30 in FY2025, a Record High for Two Consecutive Years – au Web Portal

The fact that dispensing pharmacy bankruptcies reached a record high of 30 in FY2025is a clear indication of the structural limitations of the "Monzen pharmacy" business model.The locational advantage of being close to hospitals, long considered secure, is eroding due to successive drug price revisions and a shift in evaluation towards person-to-person services. This is not merely an issue within the pharmacy industry; for prescribing medical institutions, the financial instability of their "Monzen" partners poses a risk of reduced patient convenience and disruption of the regional medical network.

From a medical M&A perspective, the traditional "prescription volume-dependent" valuation is fading, andcapital is concentrating on pharmacies with home-visit care capabilities and specialized management functions.For owners considering divestiture, it is imperative to redefine added value through functional specialization, rather than relying solely on location. Particularly, if neighboring pharmacies are struggling with cash flow, it may signal that the clinic's own patient attraction capabilities or prescription patterns are being critically evaluated by the market.

In the absence of successors, remaining passive with a "it's still okay" attitude is the biggest factor in devaluing the business. With bankruptcies becoming commonplace,early business restructuring or capital alliances to prevent mutual failurecan be considered strategic defensive measures to preserve the light of regional healthcare.